IngentaConnect Cetuximab for Recurrent andor Metastatic Squamous Cell Carcinoma ...
Links shared publicly online about this topic.
- 1,166total visits
IngentaConnect Cetuximab for Recurrent andor Metastatic Squamous Cell Carcinoma ...
View full resource at ingentaconnect.com
Tags: Cancer, Skin Cancer, Squamous Cell Carcinoma, Erbitux
Most Recently Shared on May 15, 2010 at 6:07 pm By:
Cetuximab for Recurrent andor Metastatic Squamous Cell Carcinoma of the Head and Neck: A NICE Single Technology Ap... http://bit.ly/aOyHed
Oncology Article | carcinoma of the head and neck
mdlinx.com — “Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck” View full resource at mdlinx.com
Most Recently Shared on August 26, 2011 at 1:47 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of pa... http://t.co/6VmmjYi #oncology
Otolaryngology Article | carcinoma of the head and neck
mdlinx.com — “Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck” View full resource at mdlinx.com
Most Recently Shared on August 25, 2011 at 12:52 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patient... http://t.co/pkluG6q #ENT
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study " Ann Oncol
annonc.oxfordjournals.org — “Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study " Ann Oncol” View full resource at annonc.oxfordjournals.org
Most Recently Shared on November 8, 2010 at 9:38 am By:
Oxford Journals(OUP) Medical Journal
RT @Annals_Oncology: Free: Evaluation of EGFR gene copy no. as predictive biomarker for efficacy of cetuximab... http://bit.ly/dzEDCR
ENT Medical News about Head and Neck
mdlinx.com — “Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: A NICE Single Technology Appraisal” View full resource at mdlinx.com
Most Recently Shared on June 7, 2010 at 12:27 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: A NICE Single ... http://bit.ly/9zwwm0 #ENT #mdlinx
Erbitux recognized as one of the major clinical cancer advances of 2009
news-medical.net — “The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with 1st-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).” View full resource at news-medical.net
Most Recently Shared on November 16, 2009 at 5:23 pm By:
Lung Cancer News: Erbitux recognized as one of the major clinical cancer advances of 2009: The.. http://digg.com/u1GTsp
Advertisement
